ASHES

  


Advocating Safety in Healthcare, E-Sisters

Update:

On July 20, 2018, Bayer announced it will discontinue sales of Essure in the US by the end of the year!

On April 2, 2015, three administrators and two doctors met with 30 members of the FDA. We had one hour to present information pertaining to Essure. Dr. Diana Zuckerman, president of the National Center for Health Research, led our side of the presentation. She introduced Kim Hudak, a clinical trial participant, who claims Conceptus, original manufacturer of Essure, altered her patient records before submitting them to the FDA. Next to speak was Dr. Shawn Tassone, OBGYN. He spoke about his experience as a doctor who used to insert this device, but later decided that the problems associated with it were not worth the risks after finding out one of his patients had become pregnant. Angie Firmalino spoke of her own experience after getting Essure in 2009, and how she created the Essure Problems Facebook group, and the experience of running that support group. Angela Lynch Desa described the many women who come to our page seeking help, amongst those women, two who are in current trials of the new version of Essure, ESS505. Dr. Zuckerman asked questions of the FDA, about who could be of help to those women, and what can the agency do to follow up with the allegations about altered clinical trial information. The group then followed up by going to DC to meet with representatives from the democratic and republican HELP committee. The reps have been putting pressure on the FDA to meet with us and open an investigation into the claims made against Essure.

The women of the Essure Problems Facebook group will continue to stay on top of the FDA, sending them information and proof that this device is a dangerous, and risky form of sterilization, and much less effective than most other forms of birth control out there.

We have invited each member of the FDA that attended the meeting to join the group, and see what the reality of Essure looks like out in the real world, versus what they see on paper.

We have hope that the FDA will follow through now, after meeting with us and hearing some of what we had time to present. An hour seems like a drop in a bucket, we could have spent many, many more hours there. Maybe we will have time again in the future.

Thanks go out to Dr. Zuckerman and Dr. Tassone, for speaking on our behalf, and thank you to Coco Jervis for attending with us as well.


Attendees


Thursday April 2, 2015

1. Kim Hudak- Essure Problems Administrator

2. Diana Zuckerman- National Center for Health Research

3. Angie Firmalino- Essure Problems Administrator

4. Angela Desa Lynch- Essure Problems Administrator

5. Shawn Tassone MD- OB/GYN Austin, TX

6. Coco Jervis- National Womens Health Network

7. Abiy Desta- FDA- Ombudsman abiy.desta@fda.hhs.gov

8. Greg O’Connel- FDA/CDRH/OB- Branch Chief gregory.oconnell@fda.hhs.gov

9. Anastasia Bilek- FDA/CDRH/OB- Acting DDRA anastacia.bilek@fda.hhs.gov

10. Jim Saviola- CDRH- Director Division of Bioresearch james.saviola@fda.hhs.gov

11. Christopher Ronk- CDRH/OSB/DEPI- Branch Chief christopher.ronk@fda.hhs.gov

12. Beth Fritsch- FDA/OC/OHCA- Deputy Director beth.fritsch@fda.hhs.gov

13. MaryAnn Gornick- FDA/OCD maryann.gornick@fda.hhs.gov

14. Melissa Sage- FDA/OCD- Deputy Ombudsman melissa.sage@fda.hhs.gov

15. Karen Riley- FDA/OC/OGA- Deputy For Strategy karen.riley@fda.hhs.gov

16. Elaine Blyskun- FDA/CDRH elaine.blyskun@fda.hhs.gov

17. Julia Corrrado- FDA/CDRH/ODE/DRGUD julia.corrado@fda.hhs.gov

18. Bill Maisel- FDA/CDRH william.maisel@fda.hhs.gov

19. Veronica J. Calvin- FDA/CDRH/OC/DBM- Branch Chief william.maisel@fda.hhs.gov

20. Joyce Whang- FDA/CDRH/ODG/DRGUD- Deputy Division Director joyce.whang@fda.hhs.gov

21. Jason Roberts- FDA/CDRH/ODE/DRGUD- Biomedical Engineer/Head Review jason.roberts@fda.hhs.gov

22. Mathew DiPrima- FDA/CDRH/OSEL/DAM- Materials Scientist matthew.diprima@fda.hhs.gov

23. Jeene Bailey- FDA/CDRH/DPLC/OC- CSO jeene.bailey@fda.hhs.gov

24. Eric Pahon- Office of Media Affairs,OC- Press Office eric.pahon@fda.hhs.gov

25. Danica Marinac-Dabic- FDA/CDRH/OSB/DEPI- Director, Epidemiology danica.marinac-dabic@fda.hhs.gov

26. Joy Stevens- Office of Legislation/OC- Leg. Analist joy.stevens@fda.hhs.gov

27. Kim Gross- CDRH/OSB kimberlyn.gross@fda.hhs.gov

28. Marcy Busch- FDA/OCC marcy.busch@fda.hhs.gov

29. Laura Bailis- FDA/OCC laura.bailis@fda.hhs.gov

30. Marsha Henderson- FDA/OWH- Assistant Commish marsha.henderson@fda.hhs.gov

31. Helen Barr- FDA/CDRH helen.barr@fda.hhs.gov

32. Alison Lemon- FDA/OWH- Outreach alison.lemon@fda.hhs.gov

33. Ben Fisher- FDA/ODE/DRGUD- Division Director benjamin.fisher@fda.hhs.gov

34. Herb Lerner- FDA/ODE/DRGUD- Deputy Div Director herbert.lerner@fda.hhs.gov

35. Karen Jackler- FDA/CDRH/OCD- Public Affairs Specialist karen.jackler@fda.hhs.gov

36. Ronald Swann- FDA/CDRH/OC/DMA- Supervisor CSO ronald.swann@fda.hhs.gov